Janus Henderson Group PLC Crinetics Pharmaceuticals, Inc. Transaction History

Janus Henderson Group PLC

$194 Billion
Q2 2025

A detailed history of Janus Henderson Group PLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 3,410,320 shares of CRNX stock, worth $97.1 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

3,410,320

Previous 3,424,442 0.41%

Holding current value

$97.1 Million

Previous $115 Million 14.61%

% of portfolio

0.05%

Previous 0.07%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$25.56 - $33.76 $360,958 - $476,758	-14,122 Reduced 0.41%	3,410,320 $98.1 Million
Q1 2025 May 15, 2025	BUY	$32.3 - $53.15 $20.3 Million - $33.4 Million	629,001 Added 22.5%	3,424,442 $115 Million
Q4 2024 Feb 14, 2025	BUY	$50.66 - $60.69 $18.5 Million - $22.2 Million	365,991 Added 15.06%	2,795,441 $143 Million
Q3 2024 Nov 14, 2024	SELL	$43.83 - $54.98 $1.15 Million - $1.44 Million	-26,211 Reduced 1.07%	2,429,450 $124 Million
Q2 2024 Aug 14, 2024	BUY	$42.12 - $51.91 $20.1 Million - $24.8 Million	477,489 Added 24.14%	2,455,661 $110 Million
Q1 2024 May 15, 2024	BUY	$34.76 - $46.81 $49.9 Million - $67.2 Million	1,434,909 Added 264.13%	1,978,172 $92.6 Million
Q4 2023 Feb 14, 2024	SELL	$25.62 - $37.07 $1.16 Million - $1.67 Million	-45,115 Reduced 7.67%	543,263 $19.3 Million
Q3 2023 Nov 14, 2023	BUY	$15.97 - $30.59 $1.88 Million - $3.6 Million	117,642 Added 24.99%	588,378 $17.5 Million
Q2 2023 Aug 14, 2023	BUY	$15.73 - $23.6 $857,033 - $1.29 Million	54,484 Added 13.09%	470,736 $8.48 Million
Q1 2023 May 15, 2023	BUY	$15.31 - $21.1 $152,916 - $210,746	9,988 Added 2.46%	416,252 $6.69 Million
Q4 2022 Feb 14, 2023	BUY	$15.49 - $19.05 $3.35 Million - $4.12 Million	216,416 Added 113.99%	406,264 $7.43 Million
Q3 2022 Nov 14, 2022	BUY	$18.11 - $22.37 $3.44 Million - $4.25 Million	189,848 New	189,848 $3.73 Million
Q2 2020 Aug 14, 2020	SELL	$13.04 - $23.23 $6.41 Million - $11.4 Million	-491,691 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$11.52 - $26.46 $32,474 - $74,590	2,819 Added 0.58%	491,691 $7.23 Million
Q4 2019 Feb 18, 2020	SELL	$15.24 - $25.09 $118,689 - $195,400	-7,788 Reduced 1.57%	488,872 $12.3 Million
Q3 2019 Nov 14, 2019	SELL	$14.91 - $25.01 $42,970 - $72,078	-2,882 Reduced 0.58%	496,660 $7.47 Million
Q2 2019 Jul 31, 2019	BUY	$21.48 - $27.71 $240,039 - $309,659	11,175 Added 2.29%	499,542 $12.5 Million
Q1 2019 Apr 30, 2019	SELL	$21.07 - $29.31 $873,541 - $1.22 Million	-41,459 Reduced 7.83%	488,367 $11.1 Million
Q4 2018 Feb 06, 2019	BUY	$22.4 - $35.39 $113,836 - $179,851	5,082 Added 0.97%	529,826 $15.9 Million
Q3 2018 Nov 09, 2018	BUY	$22.66 - $36.8 $11.9 Million - $19.3 Million	524,744 New	524,744 $15 Million

Others Institutions Holding CRNX

# of Institutions

232

Shares Held

90M

Call Options Held

59.7K

Put Options Held

14.8K

View Full List

About Crinetics Pharmaceuticals, Inc.

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $1.53B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

More about CRNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.

Account

Janus Henderson Group PLC Crinetics Pharmaceuticals, Inc. Transaction History